| 摘要: |
| ［摘要］ 中国临床肿瘤学会（CSCO）《乳腺癌诊疗指南》因其兼具科学性、实用性和时效性，自2017年颁布以来极大地推进了我国乳腺癌诊疗规范化。2022年4月，为了更好地满足临床需求，指南再次进行了更新。新版指南关于乳腺癌辅助治疗更新的要点主要聚焦于新辅助治疗后的辅助治疗及辅助治疗强化策略。在分类治疗基础上进一步体现分层治疗，体现新辅助治疗对术后辅助治疗的影响，充实了新辅助治疗后的辅助治疗、辅助治疗后续强化治疗内容。该文基于2022年版CSCO《乳腺癌诊疗指南》解读乳腺癌辅助治疗更新要点。 |
| 关键词: 中国临床肿瘤学会 乳腺癌 辅助治疗 更新要点 指南解读 |
| DOI：10.3969/j.issn.1674-3806.2022.11.02 |
| 分类号:R 737.9 |
| 基金项目:北京科创医学发展基金项目（编号：KC2022-ZZ-0091-7） |
|
| Interpretation of key points of adjuvant therapy updated in the 2022 CSCO Guidelines for the Diagnosis and Treatment of Breast Cancer |
|
WU Xue-xue, ZHOU Jin-mei, WANG Tao
|
|
Department of Oncology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China
|
| Abstract: |
| ［Abstract］ Chinese Society of Clinical Oncology(CSCO) Guidelines for the Diagnosis and Treatment of Breast Cancer have greatly promoted the standardized diagnosis and treatment of breast cancer in China since they were issued in 2017 due to their scientificity, practicality and timeliness. The guidelines were updated again in April 2022 to better meet clinical needs. The key points of the updated guidelines on adjuvant therapy for breast cancer mainly focus on adjuvant therapy after neoadjuvant therapy and adjuvant therapy intensification strategy. On the basis of classified therapy, it further reflects stratified therapy and the influence of neoadjuvant therapy on postoperative adjuvant therapy, and enriches the content of adjuvant therapy after neoadjuvant therapy and the intensification therapy after adjuvant therapy. Based on the 2022 CSCO Guidelines for the Diagnosis and Treatment of Breast Cancer, this paper interprets the updated key points of adjuvant therapy for breast cancer. |
| Key words: Chinese Society of Clinical Oncology(CSCO) Breast cancer Adjuvant therapy Updated key points Interpretation of guidelines |
